{"content":[{"text":"How should funding and affordability issues be addressed? \n ● Whether within a single payer public system or mixed public and private, comprehensive \n care is not achievable if underfunded. Pragmatic and workable solutions must be \n explored. \n ● The current culture of acceptance of cost-sharing of drugs must be addressed, \n recognizing that pharmaceuticals are a legitimate part of medical care. Strategies must \n overwhelmingly reduce the 22 percent of drug spending which is paid out-of-pocket by \n individual Canadians. \n ● System affordability is critical, including regarding drug prices, but the ability of Canadian \n patients to access new drugs in a timely manner must not be compromised.","bbox":{"left":0.117647,"top":0.05372,"width":0.762659,"height":0.168918}},{"text":"Important questions to ask: \n Canadians should consider change proposals as they are presented and evaluate by asking the \n following questions:","bbox":{"left":0.117647,"top":0.24122,"width":0.760867,"height":0.04959999999999998}},{"text":"Who will be covered? \n To what extent does it cover everyone and will the needs of those who are currently falling \n through the cracks be addressed?","bbox":{"left":0.117647,"top":0.309402,"width":0.7158499999999999,"height":0.04959999999999998}},{"text":"What will be covered? \n To what extent is it truly comprehensive in terms of numbers and types of drugs covered?","bbox":{"left":0.117647,"top":0.377584,"width":0.710798,"height":0.03255400000000003}},{"text":"Further documents regarding ​Best Medicines Coalition​ positions on National Pharmacare are \n posted on its ​website​.","bbox":{"left":0.117647,"top":0.428463,"width":0.7546930000000001,"height":0.04115000000000002}},{"text":"About Best Medicines Coalition \n The ​Best Medicines Coalition​ (BMC) is a national alliance of 28 patient organizations with a \n shared goal of equitable and consistent access for all Canadians to safe and effective \n medicines that improve patient outcomes. The BMC’s areas of interest include drug approval, \n assessment and reimbursement, as well as patient safety and supply issues. As an important \n aspect of its work, the BMC strives to ensure that Canadian patients have a voice and are \n meaningful participants in health policy development, specifically regarding pharmaceutical \n care. The BMC’s core activities involve issue education and advocacy, including communicating \n patient-driven consensus positions to decision makers and other stakeholders.","bbox":{"left":0.117647,"top":0.479857,"width":0.7607269999999999,"height":0.151872}}],"images_bbox":[{"left":0.210784,"top":0.651515,"width":0.578431,"height":0.297348}],"images_bbox_not_text_overlap":[{"left":0.210784,"top":0.651515,"width":0.578431,"height":0.297348}]}